Canada markets open in 4 hours 37 minutes

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
16.54-1.07 (-6.08%)
At close: 04:00PM EST
17.06 +0.52 (+3.14%)
Pre-Market: 04:03AM EST

CareDx, Inc

1 Tower Place
9th Floor
South San Francisco, CA 94080
United States
415 287 2300

IndustryDiagnostics & Research
Full Time Employees633

Key Executives

NameTitlePayExercisedYear Born
Dr. Reginald Seeto M.D., MBBSPres, CEO & Director1.51M4.46M1972
Dr. Peter Maag Ph.D.Exec. Director791.45k12.1M1967
Ms. Sasha King M.B.A.Exec. Officer628.87k1.84M1986
Mr. Marcel KonradSr. VP of Fin. & Accounting167.96k334.52k1976
Mr. Alexander L. JohnsonPres of Patient and Testing Services716.54k1.5M1974
Mr. Abhishek JainCFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting OfficerN/AN/A1976
Ms. Marica Grskovic Ph.D.Chief Operating OfficerN/AN/AN/A
Mr. Abraham Ronai Esq.Gen. Counsel, Chief Admin. & Legal Officer and Sec.N/AN/A1973
Mr. Ian CooneyVP of Investor RelationsN/AN/AN/A
Dr. Mickey Y. Kim M.D.Sr. VP of Corp. Devel. & Head of Global ProductN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Corporate Governance

CareDx, Inc’s ISS Governance QualityScore as of February 1, 2023 is 7. The pillar scores are Audit: 10; Board: 8; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.